

Special Issue

Immunomodulatory Agents for Multiple Myeloma

Message from the Guest Editors

Immunomodulatory agents (IMiDs) have changed the treatment paradigms in multiple myeloma (MM) and truly improved the survival of multiple myeloma patients. The outcomes of thalidomide-based therapy resulted in the introduction of the first effective drug with a biological mechanism of action in MM. The drug was incorporated into all phases of MM and substantially contributed to the redirection from conventional chemotherapy to immune-mediated therapy. Lenalidomide and pomalidomide, next-generation IMiDs, have become the backbone of MM treatment and most recently used combined regimens that gain their potential from the accumulative interaction of novel drugs with IMiDs. A new generation of IMiDs is being tested in both preclinical as well as clinical research. This Special Issue, “Immunomodulatory Agents for Multiple Myeloma”, aims to clarify the mechanism of action of IMiDs, their position within current strategies of MM therapy, as well as their advantages or pitfalls within routine clinical practice. We welcome original basic, translational, as well as clinical research articles and review articles leading to a comprehensive overview of IMiD-based therapy in MM.

Guest Editors

Dr. Jiří Minařík

1. Department of Hemato-Oncology, of Medicine and Dentistry, Palacky University Olomouc, 775 20 Olomouc, Czech Republic

2. University Hospital Olomouc, 779 00 Olomouc, Czech Republic

Dr. Sabina Ševčíková

Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130462

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)